Test Id : FMNPP
Motor Neuropathy Panel
Method Name
A short description of the method used to perform the test
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Quantitative Immunoturbidimetry
Quantitative Capillary Electrophoresis
Qualitative Immunofixation Electrophoresis
Colorimetric Assay
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
Alpha, Beta, and Gamma globulins
Ganglioside Ab
MAG Ab
Protein Electrophoresis
SGPG Ab
Specimen Type
Describes the specimen type validated for testing
Serum SST
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Specimen Type: Serum
Container/Tube: Serum Separator Tube (SST)
Specimen Volume: 4 mL
Collection Instructions: Draw blood in a serum gel tube(s). Spin down and send 4 mL serum refrigerated in plastic vial.
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
2 mL
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
| Other | Plasma, CSF, or other body fluids. Contaminated or heat-inactivated specimens |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum SST | Refrigerated (preferred) | 7 days | |
| Frozen | 30 days |
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Myelin Associated Glycoprotein (MAG) Antibody, IgM: 0-999
Less than 1000 TU
An elevated IgM antibody concentration greater than 999 TU against myelin-associated glycoprotein (MAG) suggests active demyelination in peripheral neuropathy. A normal concentration (less than 999 TU) generally rules out an anti-MAG antibody-associated peripheral neuropathy.
TU=Titer Units
Sulfate-3-Glucuronyl Paragloboside (SGPG) Antibody, IgM: 0.00-0.99
Less than 1.00 IV
The majority of sulfate-3-glucuronyl paragloboside (SGPG) IgM-positive sera will show reactivity against MAG. Patients who are SGPG IgM positive and MAG IgM negative may have multi-focal motor neuropathy with conduction block.
Asialo-GM1 Antibodies, IgG/IgM:
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
GM1 Antibodies, IgG/IgM:
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
GD1a Antibodies, IgG/IgM:
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
GD1b Antibodies, IgG/IgM:
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
GQ1b Antibodies, IgG/IgM:
29 IV or less: Negative
30-50 IV: Equivocal
51-100 IV: Positive
101 IV or greater: Strong Positive
Ganglioside (Asialo-GM1, GM1, GM2, GD1a, GD1b, and GQ1b) Antibodies, IgG/IgM:
Ganglioside antibodies are associated with diverse peripheral neuropathies. Elevated antibody levels to ganglioside-monosialic acid (GM1), and the neutral glycolipid, asialo GM1 are associated with motor or sensorimotor neuropathies, particularly multifocal motor neuropathy. Anti-GM1 may occur as IgM (polyclonal or monoclonal) or IgG antibodies. These antibodies may also be found in patients with diverse connective tissue diseases as well as normal individuals. GD1a antibodies are associated with different variants of Guillain-Barre syndrome (GBS) particularly acute motor axonal neuropathy while GD1b antibodies are predominantly found in sensory ataxic neuropathy syndrome. Anti-GQ1b antibodies are seen in more than 80 percent of patients with Miller-Fisher syndrome and may be elevated in GBS patients with ophthalmoplegia. The role of isolated anti-GM2 antibodies is unknown. These tests by themselves are not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.
Immunoglobulin G:
0-2 years: 242-1108 mg/dL
3-4 years: 485-1160 mg/dL
5-9 years: 514-1672 mg/dL
10-14 years: 581-1652 mg/dL
15-18 years: 479-1433 mg/dL
19 years and older: 768-1632 mg/dL
Immunoglobulin A:
0-2 years: 2-126 mg/dL
3-4 years: 14-212 mg/dL
5-9 years: 52-226 mg/dL
10-14 years: 42-345 mg/dL
15-18 years: 60-349 mg/dL
19 years and older: 68-408 mg/dL
Immunoglobulin M:
0-2 years: 21-215 mg/dL
3-4 years: 26-155 mg/dL
5-9 years: 26-188 mg/dL
10-14 years: 47-252 mg/dL
15-18 years: 26-232 mg/dL
19 years and older: 35-263 mg/dL
Total Protein, Serum:
Refer to report. Reference intervals may vary based on instrumentation.
Albumin:
3.75-5.01 g/dL
Alpha 1 Globulin:
0.19-0.46 g/dL
Alpha 2 Globulin:
0.48-1.05 g/dL
Beta Globulin:
0.48-1.10 g/dL
Gamma:
0.62-1.51 g/dL
Monoclonal Protein:
<=0.00 g/dL
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Sunday through Saturday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test was developed, and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
82784 x 3
83516 x 7
84155
84165
86334
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| FMNPP | Motor Neuropathy Panel | Not Provided |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| Z4539 | MAG Antibody, IgM | 17314-6 |
| Z4540 | SGPG Antibody, IgM | 31666-1 |
| Z4541 | Asialo-GM1 Antibodies, IgG-IgM | 44737-5 |
| Z4542 | GM1 Antibodies, IgG-IgM | 63244-8 |
| Z4543 | GD1a Antibodies, IgG-IgM | 48656-3 |
| Z4544 | GD1b Antibodies, IgG-IgM | 26870-6 |
| Z4545 | GQ1b Antibodies, IgG-IgM | 31674-5 |
| Z4546 | Immunoglobulin G | 2465-3 |
| Z4547 | Immunoglobulin A | 2458-8 |
| Z4548 | Immunoglobulin M | 2472-9 |
| Z4549 | Total Protein, Serum | 2885-2 |
| Z4550 | Albumin | 1751-7 |
| Z4551 | Alpha 1 Globulin | 2865-4 |
| Z4552 | Alpha 2 Globulin | 2868-8 |
| Z4553 | Beta Globulin | 2871-2 |
| Z4554 | Gamma | 2874-6 |
| Z4555 | Immunofixation | 25700-6 |
| Z4556 | SPEP-IFE Interpretation | 49275-1 |
| Z4557 | EER Motor Neuropathy Panel | 11526-1 |
| Z6250 | Monoclonal Protein | Not Provided |